Living With and Beyond Cancer: New Challenges

Bhuva, Neel; Li, Sonia P.; Maher, Jane

doi:10.5772/24959

Cited by 2 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Survivors at this phase are sometimes in need of further support and advice on how to progress activity, manage ongoing symptoms and return to pre-morbid status and often do not receive this [2, 3]. There are currently no recommended care pathways for lymphoma patients in remission following treatment, despite the fact that this transition period shortly after treatment has been highlighted to be particularly difficult [4].…”

Section: Introductionmentioning

confidence: 99%

Relaxation and exercise in lymphoma survivors (REIL study): a randomised clinical trial protocol

Hathiramani

Pettengell

Moir

et al. 2019

BMC Sports Sci Med Rehabil

View full text Add to dashboard Cite

Background: Lymphoma survivors commonly report ongoing complaints including fatigue, pain, depression and decreased quality of life (QoL) following treatment. Although evidence suggests that both relaxation and exercise can significantly improve such symptoms, there is no consensus on which intervention is more effective. This paper presents the REIL (Relaxation and Exercise In Lymphoma) Study protocol. The REIL study aims to compare the effect of two home-based interventionsrelaxation and exerciseon QoL in lymphoma survivors. Methods: Eligible participants (n = 36) will be randomised to a relaxation or exercise programme to perform at least three times per week. The primary outcome measure is QoL, assessed by the European Organisation for Research and Treatment of Cancer QoL Questionnaire Core 30 (EORTC QLQ-C30). Secondary outcome measures include body composition, cardiovascular status, pulmonary function, grip strength, functional exercise capacity (six minute walk test), well-being assessed by the FACT-Lym questionnaire, and psychological status assessed by the Hospital Anxiety and Depression Scale. Total duration of the study will be twelve weeks and outcome measures will be assessed at baseline, six weeks and at the end of the study. Discussion: It is anticipated that results from this preliminary study will begin to highlight effective pathways to improve QoL following chemotherapy for this population. This will better inform healthcare professionals to optimise QoL of lymphoma patients, and enable a smooth transition from being a cancer patient to survivor.

show abstract

Section: Introductionmentioning

confidence: 99%